Joanne L Dickinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9393744/publications.pdf

Version: 2024-02-01

516710 330143 47 1,422 16 37 citations h-index g-index papers 49 49 49 2355 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential. Marine Drugs, 2015, 13, 2327-2346.	4.6	245
2	Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor \hat{l}_{\pm} -induced Apoptosis. Journal of Biological Chemistry, 1995, 270, 27894-27904.	3.4	195
3	Genetic Dissection of the Human Leukocyte Antigen Region by Use of Haplotypes of Tasmanians with Multiple Sclerosis. American Journal of Human Genetics, 2002, 70, 1125-1137.	6.2	93
4	Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Multiple Sclerosis Journal, 2009, 15, 563-570.	3.0	82
5	Mutations in the <i>NDP</i> gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clinical and Experimental Ophthalmology, 2006, 34, 682-688.	2.6	76
6	The Serine Proteinase Inhibitor (Serpin) Plasminogen Activation Inhibitor Type 2 Protects against Viral Cytopathic Effects by Constitutive Interferon $\hat{l}\pm\hat{l}^{12}$ Priming. Journal of Experimental Medicine, 1998, 187, 1799-1811.	8.5	75
7	The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF- $\hat{l}\pm$ induced apoptosis. Cell Death and Differentiation, 1998, 5, 163-171.	11.2	57
8	Does the Addition of Information on Genotype Improve Prediction of the Risk of Melanoma and Nonmelanoma Skin Cancer beyond That Obtained from Skin Phenotype?. American Journal of Epidemiology, 2004, 159, 826-833.	3.4	56
9	Community Engagement for Big Epidemiology: Deliberative Democracy as a Tool. Journal of Personalized Medicine, 2014, 4, 459-474.	2.5	49
10	NLRP3 inflammasome in colitis and colitis-associated colorectal cancer. Mammalian Genome, 2018, 29, 817-830.	2.2	41
11	Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and In Vivo. Journal of Cellular Physiology, 2016, 231, 688-697.	4.1	37
12	Epigenetic regulation of prostate cancer. Clinical Epigenetics, 2011, 2, 151-169.	4.1	34
13	Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. European Journal of Human Genetics, 2009, 17, 368-377.	2.8	26
14	Regulation of the <i>ITGA2</i> gene by epigenetic mechanisms in prostate cancer. Prostate, 2015, 75, 723-734.	2.3	24
15	Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2016, 7, 46028-46041.	1.8	20
16	Ethical genetic research in Indigenous communities: challenges and successful approachesâ~†. Trends in Molecular Medicine, 2012, 18, 702-708.	6.7	18
17	Precision medicine: drowning in a regulatory soup?. Journal of Law and the Biosciences, 2016, 3, 281-303.	1.6	18
18	Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. Genome Medicine, 2017, 9, 85.	8.2	17

#	Article	IF	CITATIONS
19	Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell. Teratogenesis, Carcinogenesis, and Mutagenesis, 1993, 13, 75-88.	0.8	15
20	Emerging Putative Biomarkers: The Role of Alpha 2 and 6 Integrins in Susceptibility, Treatment, and Prognosis. Prostate Cancer, 2012, 2012, 1-9.	0.6	15
21	Runs of homozygosity and a cluster of vulvar cancer in young Australian Aboriginal women. Gynecologic Oncology, 2014, 133, 421-426.	1.4	14
22	Epigenetic regulation of the ITGB4 gene in prostate cancer. Experimental Cell Research, 2020, 392, 112055.	2.6	14
23	Sequence variants of αâ€methylacylâ€CoA racemase are associated with prostate cancer risk: A replication study in an ethnically homogeneous population. Prostate, 2008, 68, 1373-1379.	2.3	13
24	Anticipation in familial hematologic malignancies. Blood, 2011, 117, 1308-1310.	1.4	13
25	APOE Genotype and Cardio-Respiratory Fitness Interact to Determine Adiposity in 8-Year-Old Children from the Tasmanian Infant Health Survey. PLoS ONE, 2011, 6, e26679.	2.5	13
26	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e001127.	3.0	13
27	New avenues within community engagement: addressing the ingenuity gap in our approach to health research and future provision of health care. Journal of Responsible Innovation, 2014, 1, 321-328.	4.9	12
28	Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells. Journal of Cellular Physiology, 2018, 233, 3439-3453.	4.1	12
29	â€~Pollen potency': the relationship between atmospheric pollen counts and allergen exposure. Aerobiologia, 2021, 37, 825-841.	1.7	12
30	Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies. Blood, 2017, 130, 86-88.	1.4	11
31	Genetic Determinants of Epigenetic Patterns: Providing Insight into Disease. Molecular Medicine, 2015, 21, 400-409.	4.4	10
32	Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses. Clinical Epigenetics, 2016, 8, 75.	4.1	10
33	A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study. Oncology Reports, 2015, 33, 25-32.	2.6	9
34	A rare variant in <scp><i>EZH2</i></scp> is associated with prostate cancer risk. International Journal of Cancer, 2021, 149, 1089-1099.	5.1	9
35	CTLA-4 and multiple sclerosis: The A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. Journal of Neuroimmunology, 2008, 196, 139-142.	2.3	8
36	Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. Scientific Reports, 2017, 7, 17778.	3.3	8

#	Article	lF	CITATIONS
37	Evidence for a common genetic aetiology in highâ€risk families with multiple haematological malignancy subtypes. British Journal of Haematology, 2010, 150, 456-462.	2.5	7
38	The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1. Journal of Cellular Biochemistry, 2016, 117, 49-58.	2.6	7
39	Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation. Pathology, 2018, 50, 622-628.	0.6	7
40	Genetic and epigenetic variation in vulvar cancer: Current research and future clinical practice. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 406-411.	1.0	6
41	A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer. Breast Cancer Research and Treatment, 2022, 192, 89-100.	2.5	4
42	Urban–rural prostate cancer disparities in a regional state of Australia. Scientific Reports, 2022, 12, 3022.	3.3	4
43	DNase I hypersensitive sites in the 5' flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-alpha-induced transcription in monocytes. FEBS Journal, 1998, 256, 550-559.	0.2	3
44	The Familial Tasmanian Haematological Malignancies Study (FaTHMS): Its origins, its history and the phenomenon of anticipation. Transfusion and Apheresis Science, 2013, 49, 113-115.	1.0	3
45	Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C. European Journal of Cancer, 2021, 159, 52-55.	2.8	3
46	Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition. Prostate, 2022, 82, 540-550.	2.3	3
47	Recurrence patterns identify aggressive form of human papillomavirusâ€dependent vulvar cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 231-237.	1.0	1